Jenna Petersen, Andi Hila, Kiley Johnson, Ashley Daley, Colleen Caleshu
A digital hereditary cancer risk assessment tool efficiently identifies patients in need of genetic evaluation (ASD26)
A digital hereditary cancer risk assessment tool efficiently identifies patients in need of genetic evaluation (ASD26)
Jenna Petersen, Andi Hila, Kiley Johnson, Ashley Daley, Colleen Caleshu
Background
Digital tools offer a scalable approach to hereditary cancer risk assessment and have the potential to efficiently identify individuals in need of genetic evaluation in a variety of clinical settings. RISE Risk Assessment Module: Hereditary Cancer is a patient-administered digital screening tool that has been clinically validated for this purpose and is based on national testing guidelines.
Aim
To evaluate the usability and yield of a hereditary cancer risk assessment tool in ob/gyn clinics.
Methods
A retrospective chart review of consecutive patients who utilized the tool in ob/gyn clinics from July 2021 to April 2022 was completed. Variables extracted include tool usage metrics, demographics, and reported personal and family history characteristics. Usability was assessed by time taken to complete the tool and rate of completion; yield was evaluated by proportion of patients who met national genetic testing criteria.
Results
1608 patients started the tool and 1532 completed it (95.3% completion rate). The mean completion time was 3.8 minutes (standard deviation (SD) 4.7), with 84% completing the tool in under 6 minutes. The majority of patients were female (99.0%, 1516/1532) with a mean age of 38.1 (SD 12.0). Very few reported a prior positive genetic test result for hereditary cancer (0.3%, 4/1532). The tool assessed that 22.7% (348/1532) of patients met criteria for genetic testing. Few patients who met criteria had a personal history of cancer (8.3%, 29/348) or a family member with a prior positive genetic test result (3.7%, 13/348). Patients met a mean of 1.8 (SD 1.5) testing criteria, with many patients meeting criteria based on just a single criterion (59.5%, 207/348). The majority of patients who met criteria did so through only the breast/ovarian/pancreatic cancer criteria (75.6%, 263/348); 27/348 (7.8%) did so through only the colorectal criteria. 23/348 (6.6%) met criteria via both the breast/ovarian/pancreatic and the colorectal criteria.
Conclusion
Our results demonstrate that the RISE Risk Assessment Module is an efficient and scalable tool, supported by a high completion rate and fast completion time. There is a clear need for identification of hereditary cancer risk in the ob/gyn setting given that 23% of patients met criteria and very few had a prior history of cancer or a prior positive genetic test in either themselves or a relative.
Background
Digital tools offer a scalable approach to hereditary cancer risk assessment and have the potential to efficiently identify individuals in need of genetic evaluation in a variety of clinical settings. RISE Risk Assessment Module: Hereditary Cancer is a patient-administered digital screening tool that has been clinically validated for this purpose and is based on national testing guidelines.
Aim
To evaluate the usability and yield of a hereditary cancer risk assessment tool in ob/gyn clinics.
Methods
A retrospective chart review of consecutive patients who utilized the tool in ob/gyn clinics from July 2021 to April 2022 was completed. Variables extracted include tool usage metrics, demographics, and reported personal and family history characteristics. Usability was assessed by time taken to complete the tool and rate of completion; yield was evaluated by proportion of patients who met national genetic testing criteria.
Results
1608 patients started the tool and 1532 completed it (95.3% completion rate). The mean completion time was 3.8 minutes (standard deviation (SD) 4.7), with 84% completing the tool in under 6 minutes. The majority of patients were female (99.0%, 1516/1532) with a mean age of 38.1 (SD 12.0). Very few reported a prior positive genetic test result for hereditary cancer (0.3%, 4/1532). The tool assessed that 22.7% (348/1532) of patients met criteria for genetic testing. Few patients who met criteria had a personal history of cancer (8.3%, 29/348) or a family member with a prior positive genetic test result (3.7%, 13/348). Patients met a mean of 1.8 (SD 1.5) testing criteria, with many patients meeting criteria based on just a single criterion (59.5%, 207/348). The majority of patients who met criteria did so through only the breast/ovarian/pancreatic cancer criteria (75.6%, 263/348); 27/348 (7.8%) did so through only the colorectal criteria. 23/348 (6.6%) met criteria via both the breast/ovarian/pancreatic and the colorectal criteria.
Conclusion
Our results demonstrate that the RISE Risk Assessment Module is an efficient and scalable tool, supported by a high completion rate and fast completion time. There is a clear need for identification of hereditary cancer risk in the ob/gyn setting given that 23% of patients met criteria and very few had a prior history of cancer or a prior positive genetic test in either themselves or a relative.
